In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.
A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).
The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).
The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found “online first” in the journal Antiviral Chemistry & Chemotherapy.
“If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn’t want to have to take that medication via daily injection,” said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. “This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation.”
University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV’s ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.
In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.
The Latest Bing News on:
Decitabine and gemcitabine
- The Epigenome as a Therapeutic Target in Prostate Canceron April 29, 2024 at 5:00 pm
Antoinette S. Perry; R. William G. Watson; Mark Lawler; Donal Hollywood The final two classes of HDAC inhibitors consist of the electrophilic ketone, trifluoromethylketone, and the miscellaneous ...
- Bristol Myers: CHMP Recommends Approval Of Opdivo In Combination With Cisplatin And Gemcitabineon April 26, 2024 at 6:51 am
Bristol Myers Squibb (BMY) announced the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has ...
- Side Effectson April 16, 2024 at 4:01 am
Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using gemcitabine. Gemcitabine may harm an unborn baby. Your doctor should order a pregnancy ...
- Improving Cancer Care: The Role of Oral Hypomethylating Agents and Educationon April 14, 2024 at 5:00 pm
At present, patients have 2 approved options for HMAs. IV decitabine (Dacogen; MGI Pharma) and subcutaneous or IV azacitidine (Vidaza; Bristol Myers Squibb) are approved to treat MDS in the US.
- Weekly Gemcitabine and Trastuzumab in the Treatment of Patients with HER2-overexpressing Metastatic Breast Canceron April 7, 2024 at 5:00 pm
Background: The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the ...
- What Is Decitabine And Common Side Effectson March 21, 2024 at 8:55 am
Decitabine is used in the treatment of type of blood cancer called acute myeloid leukaemia (AML). It is also used to treat patients with myelodysplastic syndrome (MDS). It may be used to treat ...
- Page settingson January 19, 2024 at 9:43 am
Cytarabine is used to treat various types of cancer. Gemcitabine is used to treat certain types of cancer (including breast, lung, ovarian, pancreatic). Etoposide is used to treat certain forms of ...
- Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemiaon August 12, 2020 at 5:00 pm
Despite the superior combination treatment results with LDAC, the new drug decitabine was favored by oncologists. As a result, Stage 2 of the Phase 2 trial in AML dropped the combination treatment ...
- Gemcitabine plus capecitabine is effective in advanced pancreatic canceron March 25, 2019 at 7:48 pm
For patients with advanced or metastatic pancreatic cancer, gemcitabine is the standard therapy; however, although gemcitabine therapy increases overall survival, response rates are low.
- Side effect(s) of Decitabineon March 18, 2018 at 7:50 am
Review the side-effects of Decitabine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...
The Latest Google Headlines on:
Decitabine and gemcitabine
[google_news title=”” keyword=”Decitabine and gemcitabine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
HIV
- We have possible natural treatment for HIV, says biochemist associationon May 3, 2024 at 12:08 pm
The Biochemist Practitioners Association of Nigeria (BPAoN) says it has a possible natural treatment for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). NAN reports that Ikotun Olayemi,
- Most Pregnant Women With HIV Don't Get Recommended Vaccinationson May 2, 2024 at 2:32 pm
Among 310 pregnancies in women living with HIV, the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was administered to 32.6%, influenza vaccine to 31.6%, and both vaccines to 22.6%, Saba Berhie, MD, of Brigham and Women's Hospital in Boston, and colleagues reported in JAMA Network Open.
- Gilead gets a boost from California court in a case over slow-walking an HIV drugon May 2, 2024 at 12:25 pm
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
- From awareness to action: Mobilizing for HIV/AIDS awareness dayson April 29, 2024 at 6:22 am
National HIV/AIDS Awareness Days play a pivotal role in breaking down the stigma associated with HIV, fostering crucial conversations and actions aimed at ending the epidemic through targeted outreach and education across diverse communities.
The Latest Google Headlines on:
HIV
[google_news title=”” keyword=”HIV” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]